Cyrine E. Haidar

4.2k total citations · 3 hit papers
34 papers, 2.5k citations indexed

About

Cyrine E. Haidar is a scholar working on Pediatrics, Perinatology and Child Health, Pharmacology and Genetics. According to data from OpenAlex, Cyrine E. Haidar has authored 34 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Pediatrics, Perinatology and Child Health, 20 papers in Pharmacology and 7 papers in Genetics. Recurrent topics in Cyrine E. Haidar's work include Pharmacogenetics and Drug Metabolism (20 papers), Pharmaceutical studies and practices (12 papers) and Genomics and Rare Diseases (6 papers). Cyrine E. Haidar is often cited by papers focused on Pharmacogenetics and Drug Metabolism (20 papers), Pharmaceutical studies and practices (12 papers) and Genomics and Rare Diseases (6 papers). Cyrine E. Haidar collaborates with scholars based in United States, Canada and Netherlands. Cyrine E. Haidar's co-authors include Teri E. Klein, Kelly E. Caudle, Mary V. Relling, James M. Hoffman, Kristine R. Crews, Andrea Gaedigk, Henry M. Dunnenberger, Ulrich Broeckel, Michelle Whirl‐Carrillo and J. Kevin Hicks and has published in prestigious journals such as Journal of Clinical Oncology, PEDIATRICS and The Lancet Oncology.

In The Last Decade

Cyrine E. Haidar

33 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update

2014 453 citations Kristine R. Crews, Andrea Gaedigk et al. Clinical Pharmacology & Therapeutics profile →
Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group

2019 369 citations Kelly E. Caudle, Katrin Sangkuhl et al. Clinical and Translational Science profile →
The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin-Induced Myopathy: 2014 Update

2014 301 citations Laura B. Ramsey, Samuel G. Johnson et al. Clinical Pharmacology & Therapeutics profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Cyrine E. Haidar United States	19	1.6k	948	470	403	371	34	2.5k
Henry M. Dunnenberger United States	22	2.2k 1.4×	1.3k 1.4×	607 1.3×	412 1.0×	444 1.2×	47	3.5k
JS Leeder United States	10	1.3k 0.9×	904 1.0×	245 0.5×	451 1.1×	281 0.8×	10	2.3k
J. Kevin Hicks United States	26	990 0.6×	532 0.6×	388 0.8×	431 1.1×	665 1.8×	64	2.3k
Andrea Jorgensen United Kingdom	32	1.4k 0.9×	488 0.5×	345 0.7×	439 1.1×	468 1.3×	107	3.7k
Ron HN van Schaik Netherlands	31	1.2k 0.8×	941 1.0×	403 0.9×	780 1.9×	583 1.6×	92	3.2k
Larisa H. Cavallari United States	40	3.1k 2.0×	1.0k 1.1×	710 1.5×	532 1.3×	685 1.8×	198	5.3k
Roseann S. Gammal United States	14	976 0.6×	525 0.6×	229 0.5×	173 0.4×	183 0.5×	28	1.4k
Christina L. Aquilante United States	26	829 0.5×	468 0.5×	163 0.3×	425 1.1×	349 0.9×	87	2.3k
Deepak Voora United States	27	1.5k 1.0×	367 0.4×	321 0.7×	400 1.0×	719 1.9×	102	3.6k
Niclas Eriksson Sweden	23	2.1k 1.4×	247 0.3×	386 0.8×	321 0.8×	486 1.3×	67	4.2k

Countries citing papers authored by Cyrine E. Haidar

Since Specialization

Citations

This map shows the geographic impact of Cyrine E. Haidar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cyrine E. Haidar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cyrine E. Haidar more than expected).

Fields of papers citing papers by Cyrine E. Haidar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cyrine E. Haidar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cyrine E. Haidar. The network helps show where Cyrine E. Haidar may publish in the future.

Co-authorship network of co-authors of Cyrine E. Haidar

This figure shows the co-authorship network connecting the top 25 collaborators of Cyrine E. Haidar. A scholar is included among the top collaborators of Cyrine E. Haidar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cyrine E. Haidar. Cyrine E. Haidar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Caudle, Kelly E., Michelle Whirl‐Carrillo, Mary V. Relling, et al.. (2025). Advancing Clinical Pharmacogenomics Worldwide Through the Clinical Pharmacogenetics Implementation Consortium ( CPIC ). Clinical Pharmacology & Therapeutics. 118(6). 1512–1522. 2 indexed citations

Eum, Seenae, Zeruesenay Desta, Rachel F. Tyndale, et al.. (2024). Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2B6 Genotype and Methadone Therapy. Clinical Pharmacology & Therapeutics. 116(4). 932–938. 9 indexed citations

Yang, Wenjian, Keito Hoshitsuki, Mary V. Relling, et al.. (2024). Clinical Actionability of the NUDT15 *4 (p.R139H) Allele and Its Association With Hispanic Ethnicity. Clinical Pharmacology & Therapeutics. 117(3). 724–731.

Haidar, Cyrine E., et al.. (2024). Assessment of the current status of real-world pharmacogenomic testing: informed consent, patient education, and related practices. Frontiers in Pharmacology. 15. 1355412–1355412. 4 indexed citations

Turner, Amy, Cyrine E. Haidar, Wenjian Yang, et al.. (2023). Updated DPYDHapB3 haplotype structure and implications for pharmacogenomic testing. Clinical and Translational Science. 17(1). e13699–e13699. 23 indexed citations

Gammal, Roseann S., Munir Pirmohamed, Andrew A. Somogyi, et al.. (2022). Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype. Clinical Pharmacology & Therapeutics. 113(5). 973–985. 28 indexed citations

Haidar, Cyrine E., et al.. (2021). ASHP Statement on the Pharmacist’s Role in Clinical Pharmacogenomics. American Journal of Health-System Pharmacy. 79(8). 704–707. 58 indexed citations

Turner, Amy, Praful Aggarwal, Erin C. Boone, et al.. (2021). Identification of CYP2D6 Haplotypes that Interfere with Commonly Used Assays for Copy Number Variation Characterization. Journal of Molecular Diagnostics. 23(5). 577–588. 10 indexed citations

Yang, Wenjian, Cyrine E. Haidar, Jane S. Hankins, et al.. (2018). Concordance between glucose-6-phosphate dehydrogenase (G6PD) genotype and phenotype and rasburicase use in patients with hematologic malignancies. The Pharmacogenomics Journal. 19(3). 305–314. 7 indexed citations

10.

Rosenthal, Meagen, et al.. (2017). Preemptive pharmacogenetic testing: exploring the knowledge and perspectives of US payers. Genetics in Medicine. 21(5). 1224–1232. 62 indexed citations

11.

Gammal, Roseann S., Kristine R. Crews, Cyrine E. Haidar, et al.. (2016). Pharmacogenetics for Safe Codeine Use in Sickle Cell Disease. PEDIATRICS. 138(1). 56 indexed citations

12.

Pasternak, Amy L., Kristine R. Crews, Kelly E. Caudle, et al.. (2016). The Impact of the UGT1A1*60 Allele on Bilirubin Serum Concentrations. Pharmacogenomics. 18(1). 5–16. 3 indexed citations

13.

Hoffman, James M., Cyrine E. Haidar, Mark R. Wilkinson, et al.. (2014). PG4KDS: A model for the clinical implementation of pre‐emptive pharmacogenetics. American Journal of Medical Genetics Part C Seminars in Medical Genetics. 166(1). 45–55. 205 indexed citations

14.

Relling, Mary V., Ellen M. McDonagh, Tai‐Tsung Chang, et al.. (2014). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Rasburicase Therapy in the Context of G6PD Deficiency Genotype. Clinical Pharmacology & Therapeutics. 96(2). 169–174. 92 indexed citations

15.

Ramsey, Laura B., Samuel G. Johnson, Kelly E. Caudle, et al.. (2014). The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin-Induced Myopathy: 2014 Update. Clinical Pharmacology & Therapeutics. 96(4). 423–428. 301 indexed citations breakdown →

16.

Crews, Kristine R., Andrea Gaedigk, Henry M. Dunnenberger, et al.. (2014). Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update. Clinical Pharmacology & Therapeutics. 95(4). 376–382. 453 indexed citations breakdown →

17.

Barbarino, Julia M., Cyrine E. Haidar, Teri E. Klein, & Russ B. Altman. (2013). PharmGKB summary. Pharmacogenetics and Genomics. 24(3). 177–183. 82 indexed citations

18.

Bell, Gillian C., Kristine R. Crews, Mark R. Wilkinson, et al.. (2013). Development and use of active clinical decision support for preemptive pharmacogenomics. Journal of the American Medical Informatics Association. 21(e1). e93–e99. 159 indexed citations

19.

Hicks, J. Kevin, Kristine R. Crews, James M. Hoffman, et al.. (2012). A Clinician-Driven Automated System for Integration of Pharmacogenetic Interpretations Into an Electronic Medical Record. Clinical Pharmacology & Therapeutics. 92(5). 563–566. 77 indexed citations

20.

Haidar, Cyrine E. & Sima Jeha. (2010). Drug interactions in childhood cancer. The Lancet Oncology. 12(1). 92–99. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact